Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01993784 | Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 9 | Peking UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01688700 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Sep 20, 2012 | clinicaltrials |
| NCT01402180 |
| Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy(Nimotuzumab) |
| unknown |
| Phase 2 / Phase 3 |
| 128 |
| Fudan UniversityOTHER |
| 1 |
| Jul 26, 2011 |
| clinicaltrials |
| NCT01391572 | A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer | unknown | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT01336049 | Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | unknown | Phase 2 | 70 | Peking UniversityOTHER | 1 | Apr 15, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Nov 25, 2013source: clinicaltrials